Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oneness Biotech Co., Ltd. (4743.TWO)
Taipei, TW
Oneness Biotech Co., Ltd., headquartered in Taipei City, Taiwan, functions as a biopharmaceutical enterprise primarily dedicated to the discovery and advancement of novel therapeutic agents, in addition to selling pharmaceutical and health-related merchandise. The company's operations are divided into its New Drug Research and Development segment and its Agricultural Products Cultivation segment. Its advanced therapeutic candidate, ON101, is currently undergoing Phase III clinical trials for the treatment of chronic diabetic foot ulcers. Additionally, OB318, an experimental anti-cancer drug, is progressing through Phase I clinical evaluation. The company's development pipeline further includes FB704A, which has successfully concluded its Phase I clinical trial for addressing rheumatoid arthritis and systemic sclerosis. Furthermore, FB825 is currently in Phase II clinical trials, targeting conditions like atopic dermatitis, various allergic diseases, and asthma. In its earlier stages, FB918, a human monoclonal antibody aimed at allergic asthma, is undergoing pre-clinical development. Beyond its pharmaceutical endeavors, Oneness Biotech also oversees agricultural cultivation and trading activities, encompassing the distribution of farm produce. The company was established and began operations in 2008.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.78% | -3.19% | -3.01% | -14.43% | -17.83% | -7.19% | -15.96% | -72.11% | -71.72% | +130.05% | +433.06% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+9.5% ★ Q1'26: +45.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+10.7% Q1'26: +8.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-445.2% Q1'26: -83.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-621.9% Q1'26: -524.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-16.0% ★ Q1'26: -15.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.4% ★ Q1'26: +1.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.79× Q1'26: -0.48× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
1.07B
est: 1.06B (+0.2%)
|
86.78M
est: 101.93M (-14.9%)
|
117.93M
est: 125.00M (-5.7%)
|
129.12M
est: 527.00M (-75.5%)
|
527.00M
527.00M – 527.00M
+0.0% YoY
|
| EBITDA |
860.35M
est: -678.74M (+226.8%)
|
-674.23M
est: -65.08M (-936.0%)
|
-685.71M
est: -79.81M (-759.1%)
|
-469.09M
est: -336.50M (-39.4%)
|
-336.50M
-336.50M – -336.50M
+0.0% YoY
|
| EBIT |
-241.45M
est: -777.33M (+68.9%)
|
-1.10B
est: -74.53M (-1,371.3%)
|
-1.14B
est: -91.41M (-1,147.3%)
|
-803.01M
est: -385.38M (-108.4%)
|
-385.38M
-385.38M – -385.38M
+0.0% YoY
|
| Net Income |
359.98M
est: 183.88M (+95.8%)
|
-1.31B
est: -983.64M (-33.5%)
|
-1.17B
est: -742.84M (-56.8%)
|
-1.04B
est: -603.86M (-73.0%)
|
-603.86M
-603.86M – -603.86M
+0.0% YoY
|
| SGA |
166.83M
est: 1.80B (-90.7%)
|
176.64M
est: 156.46M (+12.9%)
|
223.55M
est: 191.88M (+16.5%)
|
233.09M
est: 808.98M (-71.2%)
|
808.98M
808.98M – 808.98M
+0.0% YoY
|
| EPS |
0.82
est: 0.39 (+112.9%)
|
-2.77
est: -2.05 (-35.0%)
|
-2.44
est: -1.55 (-57.4%)
|
-2.18
est: -1.26 (-73.0%)
|
-1.26
-1.26 – -1.26
+0.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.05% | 36.7K | 0.74% |
| 2 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.04% | 134.2K | 0.74% |
| 3 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 127.0K | 0.72% |
| 4 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 144.1K | 0.55% |
| 5 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.87M | 0.06% |
| 6 | iShares Core MSCI Emerging Markets IMI Index ETF XEC.TO | 0.01% | 268.3K | 0.28% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 138.4K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 61.4K | 0.48% |
| 9 | iShares Core MSCI Emerging Markets ETF IEMG | 0.00% | 6.77M | 0.09% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 6.83M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shuling Cheng | President | 11M | female |
| Yung-Chi Cheng | Deputy General Manager of Business Department | 3M | male |
| Tzu-Chun Yang | Associate General Manager of Information Technology Department | 2M | male |
| Nien-Yi Chen | Deputy General Manager of Antibody New Drug Division; | 911.0K | male |
| Kung-Ming Lu | Director of Operation Center | — | male |
| Jui-Ching Chen | Director of New Drug Development Department | — | — |
| Ting-Fang Chen | Financial Officer & Acting Spokesperson | — | — |
| Ai-Chia Yu | Accounting Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4743.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
